scholarly journals ROLE OF INFECTION AND CHRONIC INFLAMMATION IN THE PATHOGENESIS OF NON-HODGKINS LYMPHOMA

2009 ◽  
Vol 5 (Issue 3-4) ◽  
pp. 11-17
Author(s):  
Hamdy Zawam
1997 ◽  
Vol 26 (1-2) ◽  
pp. 127-130 ◽  
Author(s):  
M. D. McColl ◽  
I. O. Singer ◽  
R. C. Tait ◽  
I. R. R. McNeil ◽  
R. L. C. Cumming ◽  
...  

1970 ◽  
Vol 39 (136) ◽  
pp. 326-328
Author(s):  
Rahjan Agrawal ◽  
Y K Jain

Sputum cytology is an important investigation in the diagnosis of lung malignancies.The study was thus aimed at evaluating the role of sputum smears in bronchogeniccarcinomas. A total of 80 cases were included in the study. The positivity rate forvarious subtypes was squamous cell carcinoma (50%), large cell carcinoma (50%),non-hodgkins lymphoma (50%), secondaries (40%), small cell carcinoma (37.5%),hodgkins lymphoma (33.33%) and adenocarcinoma (30.77%). Peripherally locatedmalignant lesions have a reduced chance of being expectorated out in the sputum.Early morning samples are the best sample for diagnosis.It was thus concluded that Sputum cytology is important as an investigation to becarried out simultaneously with other techniques in detecting occult malignancies.KEY WORDS: Sputum Cytology, Bronchogenic Carcinoma


Author(s):  
Darshana Kottahachchi ◽  
Chamila Nandasena ◽  
Sachini Gallage ◽  
Sasikala Suresh

2001 ◽  
Vol 2 (4) ◽  
pp. 301-311 ◽  
Author(s):  
A. J. Grillo-Lopez ◽  
B.K. Dallaire ◽  
A. McClure ◽  
R. Weaver ◽  
C. Varns ◽  
...  

2020 ◽  
Vol 21 (15) ◽  
pp. 1558-1565
Author(s):  
Matteo Santoni ◽  
Francesco Massari ◽  
Liang Cheng ◽  
Alessia Cimadamore ◽  
Marina Scarpelli ◽  
...  

The carcinogenesis of prostate cancer (PCa) results from a complex series of events. Chronic inflammation and infections are crucial in this context. Infiltrating M2 type macrophages, as well as neutrophils and T lymphocytes, contribute to PCa development, progression and response to therapy. The preliminary findings on the efficacy of immunotherapy in patients with PCa were not encouraging. However, a series of studies investigating anti-PD-L1 agents such as Atezolizumab, Avelumab and Durvalumab used alone or in combination with other immunotherapies, chemotherapy or locoregional approaches are in course in this tumor. In this review, we illustrate the role of immune cells and PD-L1 expression during PCa carcinogenesis and progression, with a focus on ongoing clinical trials on anti-PD-L1 agents in this context.


Author(s):  
Sridhar Muthusami ◽  
R. Ileng Kumaran ◽  
Kokelavani Nampalli Babu ◽  
Sneha Krishnamoorthy ◽  
Akash Guruswamy ◽  
...  

: Chronic inflammation can lead to the development of many diseases including cancer. Inflammatory bowel disease (IBD) that includes both ulcerative colitis (UC) and Crohn's disease (CD) are risk factors for the development of colorectal cancer (CRC). Many cytokines produced primarily by the gut immune cells either during or in response to localized inflammation in the colon and rectum are known to stimulate the complex interactions between the different cell types in the gut environment resulting in acute inflammation. Subsequently, chronic inflammation together with genetic and epigenetic changes has been shown to lead to the development and progression of CRC. Various cell types present in the colon such as enterocytes, Paneth cells, goblet cells and macrophages express receptors for inflammatory cytokines and respond to tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), IL-6 and other cytokines. Among the several cytokines produced, TNF-α and IL-1β are the key proinflammatory molecules that play critical roles in the development of CRC. The current review is intended to consolidate the published findings to focus on the role of proinflammatory cytokines, namely TNF-α and IL-1β, on inflammation (and the altered immune response) in the gut, to better understand the development of CRC in IBD, using various experimental model systems, preclinical and clinical studies. Moreover, this review also highlights the current therapeutic strategies available (monotherapy and combination therapy), to alleviate the symptoms or treat inflammationassociated CRC by using monoclonal antibodies or aptamers to block proinflammatory molecules, inhibitors of tyrosine kinases in inflammatory signaling cascade, competitive inhibitors of proinflammatory molecules, and the nucleic acid drugs like small activating RNAs (saRNAs) or microRNA (miRNA) mimics to activate tumor suppressor or repress oncogene/proinflammatory cytokine gene expression.


Pathology ◽  
1991 ◽  
Vol 23 (2) ◽  
pp. 164-166 ◽  
Author(s):  
Frances M. Boyle ◽  
Kerry McD. Taylor ◽  
John R. Bell

Sign in / Sign up

Export Citation Format

Share Document